{"protocolSection": {"identificationModule": {"nctId": "NCT00792935", "orgStudyIdInfo": {"id": "0941-017"}, "secondaryIdInfos": [{"id": "2008_589"}, {"id": "CTRI/2009/091/000154", "type": "REGISTRY", "domain": "CTRI"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)", "officialTitle": "A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy"}, "statusModule": {"statusVerifiedDate": "2015-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-01"}, "primaryCompletionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-11-14", "studyFirstSubmitQcDate": "2008-11-17", "studyFirstPostDateStruct": {"date": "2008-11-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-06-28", "resultsFirstSubmitQcDate": "2012-08-31", "resultsFirstPostDateStruct": {"date": "2012-10-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-12-16", "lastUpdatePostDateStruct": {"date": "2015-12-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking metformin for type 2 diabetes."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 143, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-0941", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0941", "Drug: Metformin"]}, {"label": "Glimepiride", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Glimepiride", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "MK-0941", "description": "MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.", "armGroupLabels": ["MK-0941"]}, {"type": "DRUG", "name": "Glimepiride", "description": "Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.", "armGroupLabels": ["Glimepiride"], "otherNames": ["Amaryl\u00ae"]}, {"type": "DRUG", "name": "Metformin", "description": "The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], the participant should remain on the same metformin dose throughout the study.", "armGroupLabels": ["Glimepiride", "MK-0941"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 6 in 24-hour Weighted Mean Glucose", "description": "Weighted Mean Glucose (WMG) is a measure of the amount of glucose in the blood over a period of 24 hours. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The \"weighted\" mean was used to avoid over-representation of post-meal glucose values.", "timeFrame": "Baseline and Week 6"}, {"measure": "Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)", "description": "Hypoglycemic episodes are defined as either a fingerstick glucose\n\nmeasurement of \u226470 mg/dL \\[3.9 mmol/L\\] with or without symptoms or symptomatic hypoglycemia.", "timeFrame": "Baseline to Week 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Between the ages of 18 and 70\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or ketoacidosis.\n* Patient is on a weight loss program and is not in the maintenance phase or is taking weight loss medication.\n* Patient has had surgery within 30 days of starting the study or has planned major surgery during the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MK-0941", "description": "Participants receive MK-0941 5 mg or 10 mg tablets, orally, TID and placebo tablets matching glimepiride 1 mg or 2 mg, orally, QD for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}, {"id": "FG001", "title": "Glimepiride", "description": "Participants receive glimepiride 1 mg or 2 mg tablets, orally, QD and placebo tablets matching MK-0941 5 mg or 10 mg, orally, TID for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "72"}, {"groupId": "FG001", "numSubjects": "71"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "68"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-0941", "description": "Participants receive MK-0941 5 mg or 10 mg tablets, orally, TID and placebo tablets matching glimepiride 1 mg or 2 mg, orally, QD for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}, {"id": "BG001", "title": "Glimepiride", "description": "Participants receive glimepiride 1 mg or 2 mg tablets, orally, QD and placebo tablets matching MK-0941 5 mg or 10 mg, orally, TID for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "143"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.8", "spread": "9.5"}, {"groupId": "BG001", "value": "55.2", "spread": "9.8"}, {"groupId": "BG002", "value": "55", "spread": "9.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "55"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "88"}]}]}]}, {"title": "Mean 24-Hour Weighted Mean Glucose at Baseline", "description": "Weighted Mean Glucose (WMG) is a measure of the amount of glucose in the blood over a period of 24 hours. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The \"weighted\" mean was used to avoid over-representation of post-meal glucose values.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "178.8", "spread": "33.9"}, {"groupId": "BG001", "value": "184.4", "spread": "38.4"}, {"groupId": "BG002", "value": "181.6", "spread": "36.2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 6 in 24-hour Weighted Mean Glucose", "description": "Weighted Mean Glucose (WMG) is a measure of the amount of glucose in the blood over a period of 24 hours. The WMG was derived from multiple glucose values collected during both fasting and post-meal periods. The \"weighted\" mean was used to avoid over-representation of post-meal glucose values.", "populationDescription": "The full analysis set (FAS) population included all randomized participants who had efficacy measurements at baseline or a post-randomization visit).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "MK-0941", "description": "Participants receive MK-0941 5 mg or 10 mg tablets, orally, TID and placebo tablets matching glimepiride 1 mg or 2 mg, orally, QD for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants receive glimepiride 1 mg or 2 mg tablets, orally, QD and placebo tablets matching MK-0941 5 mg or 10 mg, orally, TID for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-43.4", "lowerLimit": "-50.0", "upperLimit": "-36.8"}, {"groupId": "OG001", "value": "-44.2", "lowerLimit": "-50.9", "upperLimit": "-37.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Using a standard deviation of 23.5 mg/dL, a sample size of at least 65 participants per treatment group would be required to have an 80% power to detect a true difference of 12.5 mg/dL between MK-0941 and glimepiride as measured by change from baseline in 24-hour WMG at Week 6.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.847", "statisticalMethod": "Constrained longitudinal analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.9", "ciUpperLimit": "9.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.4"}]}, {"type": "PRIMARY", "title": "Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)", "description": "Hypoglycemic episodes are defined as either a fingerstick glucose\n\nmeasurement of \u226470 mg/dL \\[3.9 mmol/L\\] with or without symptoms or symptomatic hypoglycemia.", "populationDescription": "All patients as treated (APaT) defined as all randomized participants who received at least one dose of MK-0941 or glimepiride.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to Week 6", "groups": [{"id": "OG000", "title": "MK-0941", "description": "Participants receive MK-0941 5 mg or 10 mg tablets, orally, TID and placebo tablets matching glimepiride 1 mg or 2 mg, orally, QD for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants receive glimepiride 1 mg or 2 mg tablets, orally, QD and placebo tablets matching MK-0941 5 mg or 10 mg, orally, TID for 6 weeks. Up-titration and down-titration of the dose could occur to achieve optimal individual glucose control. In addition, all participants received a maximum tolerated dose of metformin \\[(i.e., \u22651500 mg/day and \u22642550 mg/day (or \u22643000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\\], after a 4-week dose titration/dose stabilization period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "71"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "37"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.361", "statisticalMethod": "Miettinen & Nurminen method.", "paramType": "Proportions", "paramValue": "-7.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.6", "ciUpperLimit": "8.7", "estimateComment": "The estimated value represents the difference in percentages, MK-0941 minus Glimepiride."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "14 weeks", "description": "All randomized participants who received at least one dose of MK-0941 or glimepiride. Assessments during regular visits to the site (every 2 to 4 weeks).", "eventGroups": [{"id": "EG000", "title": "MK-0941", "description": "All patients as treated (APaT) defined as all randomized participants who received at least one dose of MK-0941.", "seriousNumAffected": 1, "seriousNumAtRisk": 72, "otherNumAffected": 31, "otherNumAtRisk": 72}, {"id": "EG001", "title": "Glimepiride", "description": "All patients as treated (APaT) defined as all randomized participants who received at least one dose of glimepiride.", "seriousNumAffected": 1, "seriousNumAtRisk": 71, "otherNumAffected": 25, "otherNumAtRisk": 71}], "seriousEvents": [{"term": "Comminuted fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 71}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 89, "numAffected": 28, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 78, "numAffected": 23, "numAtRisk": 71}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Canada", "Colombia", "Denmark", "Estonia", "Finland", "India", "Ireland", "Italy", "Malaysia", "Norway", "Poland", "Russian Federation", "Sweden", "Taiwan", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000057619", "term": "Glimepiride"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}]}}, "hasResults": true}